Gland Pharma Limited Bombay S.E.

GLAND

INE068V01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:53 15/07/2024 pm IST			5-day change	1st Jan Change
2,001 ^INR	-1.39%		+6.14%	+4.01%

20/06	Fosun Pharma Trims Stake in Gland Pharma to 51.83%	MT
18/06	Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million	CI

Gland Pharma Limited Announces Unaudited Earnings Results for the Year Ended Dec. 31, 2018

January 24, 2019 at 08:18 pm IST

Gland Pharma Limited announced unaudited earnings results for the year ended Dec. 31, 2018. For the year, net profit (after tax) was RMB 425 million against RMB 330 million a year ago.

Latest news about Gland Pharma Limited

Fosun Pharma Trims Stake in Gland Pharma to 51.83%	20/06	MT
Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million	18/06	CI
Gland Pharma Limited Announces Management Changes	07/06	CI
Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively	31/05	CI
Gland Pharma Gets Zero Observations from US FDA for API Facility in Andhra Pradesh, India	24/05	MT
Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy	23/05	MT
Gland Pharma Posts Surge in Fiscal Q4 Consolidated Net Profit	23/05	MT
Transcript : Gland Pharma Limited, Q4 2024 Earnings Call, May 22, 2024	22/05
Gland Pharma Limited Board Recommends Final Dividend for the Fiscal Year Ending March 31, 2024	22/05	CI
Gland Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	22/05	CI
Gland Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	22/05	CI
Gland Pharma Gets US FDA's Approval for Generic ALS Drug	07/05	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Edaravone Injection	07/05	CI
Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection	07/05	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Plerixafor Injection	07/05	CI
KKR to buy India's Healthium Medtech at $839 million valuation, sources say	06/05	RE
Gland Pharma Names COO	29/04	MT
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	29/04	CI
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges	29/04	MT
Gland Pharma Receives Approval for Cetrorelix Acetate for Injection	29/04	CI
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	08/04	CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	08/04	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	06/04	CI
Gland Pharma COO, Chief Technical Officer Step Down	25/03	MT
Gland Pharma Limited Announces Change in Management	25/03	CI

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

Sector

Pharmaceuticals

Calendar

17/07/2024 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Gland Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,001 INR

Average target price

1,869 INR

Spread / Average Target

-6.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+63.05%	85TCr
NOVO NORDISK A/S	+39.42%	64TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+14.19%	25TCr
ROCHE HOLDING AG	+5.81%	23TCr
NOVARTIS AG	+16.77%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals

Gland Pharma Limited Bombay S.E.

Equities

GLAND

INE068V01023

Pharmaceuticals

Gland Pharma Limited Announces Unaudited Earnings Results for the Year Ended Dec. 31, 2018

Latest news about Gland Pharma Limited

Chart Gland Pharma Limited

Company Profile

Income Statement Evolution

Ratings for Gland Pharma Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals